Minaprine
As of the edition of 20 October 2026, Minaprine is a small molecule: withdrawn from the market in 1996; acts on ACHE, CHRM1 and DRD1 and 5 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 1996
- Kind
- Small molecule
- Withdrawn from market
- 1 January 1996 (in some regions)
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 |
| DRD2 | Dopamine receptor D2 | P14416 |
| MAOA | Amine oxidase [flavin-containing] A | P21397 |
| DRD1 | Dopamine receptor D1 | P21728 |
| ACHE | Acetylcholinesterase | P22303 |
| HTR2A | 5-hydroxytryptamine receptor 2A | P28223 |
| HTR2C | 5-hydroxytryptamine receptor 2C | P28335 |
| HTR2B | 5-hydroxytryptamine receptor 2B | P41595 |